Search

Background: In hyperthyroidism, oxidative stress is produced due to an increase in the production of reactive oxygen species as a result of the hypersecretion of thyroid hormone. The objectives of this study were to determine the effect of methimazole on three oxidative stress markers in patients with hyperthyroidism in the population of Kutahya City, Turkey. Materials & Methods: This quasi-experimental study was conducted in Faculty of Medicine, Kutahya Health Sciences University, Kutahya, Turkey from August 2020 to September 2021. Thirty newly diagnosed hyperthyroidism patients were included. Methimazole treatment was given to all patients for three months. Two patients were dropped due to allergic reactions. Total antioxidant status (TAS) and total oxidant status (TOS) were measured, and oxidative stress index (OSI) was calculated at the time of diagnosis and after three months of methimazole treatment. All data was analyzed by mean and SD with 95%CI. Three hypotheses were verified by paired samples t test. Results: In a sample of 30 hyperthyroidism patients, mean TAS level was 1.52 mmol Trolox Eq/L before treatment. It increased significantly to 1.58 with methimazole treatment (p=.013). Mean TOS level was 10.40 µmol H2O2 Eq/L before treatment. It decreased significantly to 6.79 with methimazole treatment (p=<.0001). Mean OSI level was 0.68 arbitrary units before treatment. It decreased significantly to 0.44 with methimazole treatment (p=<.0001). Conclusion: Methimazole drug treatment for three months for hyperthyroidism increased total antioxidant status, while decreased total oxidant status and oxidative stress index in population of Kutahya City, Turkey. [ABSTRACT FROM AUTHOR]

Background: Overproduction of oxygen-related free radicals and inadequate antioxidant defense are critical in hypothyroidism, as they might lead to future life-threatening diseases. The objectives of this study were to compare serum levels of oxidative stress markers; total oxidant status (TOS), total antioxidant status (TAS), oxidative stress index (OSI), paraoxonase-1 (PON-1), and arylesterase (ARYL) in patients with subclinical hypothyroidism (SH) and overt hypothyroidism (OH) versus healthy controls in population of Kutahya city, Turkey. Materials & Methods: This cross-sectional study was conducted at Department of Biochemistry, Faculty of Medicine, Kutahya University of Health Sciences, Kutahya, Turkey, from July to December, 2016. Three study groups of 45 each were formed as healthy controls, patients with SH and OH. Serum levels of TOS, TAS, OSI, PON-1, and ARYL were five research variables with ratio scale, but skewed, so described by median and IQR with 95% Cl. Kruskal-Wallis and multiple comparison tests were used for hypotheses testing. Results: Serum levels of TOS and OSI were higher in SH group (p-values 0.032; <.0001; respectively) and OH group (p-values <.0001; <.0001, respectively) than healthy controls, while serum levels of TAS, PON-1 and ARYL were lower in SH group (p-values <.0001; <.0001; <.0001, respectively) and OH group (p-values <.0001; <.0001; <.0001, respectively) than control group. Conclusion: Our study showed that serum levels of TOS and OSI were higher in subclinical and overt hypothyroidism than in healthy controls; while serum levels of TAS, PON-1, and ARYL were lower in subclinical and overt hypothyroidism than in healthy controls. [ABSTRACT FROM AUTHOR]